Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy
Huan Song(Fudan University), Jie Liu(Fudan University), Maolin Ye(Fudan University), Shaocong Mo(Fudan University), Zheng Gong(Fudan University), Haoshu Cui(Fudan University), Yujen Tseng(Fudan University), Bin Zhong(Fudan University), Xuanxuan Pan(Fudan University), Bryan Jin(Fudan University), Jiayue Zheng(Fudan University), Can Cui(Xi'an University of Technology), Lin Chen(Fudan University), Qi Zhou(Fudan University), Guohong Wang(Fudan University), Wanwei Zheng(Fudan University), Yuru Shen(Fudan University), Feifei Luo(Jiangxi University of Traditional Chinese Medicine)
Cited by 66
Related Papers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
|Journal of Neuroinflammation|2018|264
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
|Journal of Hematology & Oncology|2020|183
TLR2 Promotes Glioma Immune Evasion by Downregulating MHC Class II Molecules in Microglia
|Cancer Immunology Research|2018|137
TLR1/TLR2 Agonist Induces Tumor Regression by Reciprocal Modulation of Effector and Regulatory T Cells
|The Journal of Immunology|2011|132